Llwytho...
Receptor Activator of Nuclear Factor Kappa B (RANK) Expression in Primary Breast Cancer Correlates with Recurrence Free Survival and Development of Bone Metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657)
PURPOSE: The Receptor Activator of Nuclear Factor Kappa B (RANK)/RANK ligand (RANKL)/Osteoprotegerin (OPG) axis may contribute to the development of bone metastases (BM). We studied gene expression in this pathway in primary breast cancer (BC) to determine correlations with clinical characteristics...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Breast Cancer Res Treat |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5725604/ https://ncbi.nlm.nih.gov/pubmed/28577080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4318-1 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|